Skip to Main content Skip to Navigation
Journal articles

Targeted therapies in metastatic renal cancer in 2009.

Abstract : The development of targeted molecules in renal carcinogenesis changed the therapeutic approaches of treatment for metastatic clear cell renal cell carcinoma. Four available drugs are currently available, i.e. bevacizumab, sunitinib, sorafenib and temsirolimus, but other molecules and combined therapy are under investigation. In this review we assess published reports of these targeted therapies and discuss the novel promising molecules targeting vascular endothelial growth factor and its receptors, the mammalian target of rapamycin and epithelial growth factor cascade.
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00373565
Contributor : Hervé de Villemeur <>
Submitted on : Monday, April 6, 2009 - 2:40:02 PM
Last modification on : Thursday, October 8, 2020 - 3:06:43 AM

Identifiers

Citation

Laurence Bastien, Stéphane Culine, Bernard Paule, Souhil Ledbai, Jean-Jacques Patard, et al.. Targeted therapies in metastatic renal cancer in 2009.. BJU International, Wiley, 2009, 103 (10), pp.1334-42. ⟨10.1111/j.1464-410X.2009.08454.x⟩. ⟨inserm-00373565⟩

Share

Metrics

Record views

219